- Hong Kong
- /
- Life Sciences
- /
- SEHK:2268
WuXi XDC Cayman First Half 2024 Earnings: EPS: CN¥0.41 (vs CN¥0.18 in 1H 2023)
WuXi XDC Cayman (HKG:2268) First Half 2024 Results
Key Financial Results
- Revenue: CN¥1.67b (up 68% from 1H 2023).
- Net income: CN¥488.2m (up 176% from 1H 2023).
- Profit margin: 29% (up from 18% in 1H 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.41 (up from CN¥0.18 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
WuXi XDC Cayman Earnings Insights
Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.
Performance of the market in Hong Kong.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on WuXi XDC Cayman's balance sheet.
Valuation is complex, but we're here to simplify it.
Discover if WuXi XDC Cayman might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2268
WuXi XDC Cayman
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
High growth potential with solid track record.